An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, View ORCID ProfileRajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, View ORCID ProfileSaye Khoo, Andrew Owen, View ORCID ProfileGareth Griffiths, Thomas E Fletcher on behalf of the AGILE platform
doi: https://doi.org/10.1101/2021.09.10.21263376
Lauren E Walker
1University of Liverpool
2Liverpool University Hospitals NHS Foundation Trust
Richard FitzGerald
2Liverpool University Hospitals NHS Foundation Trust
Geoffrey Saunders
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Rebecca Lyon
2Liverpool University Hospitals NHS Foundation Trust
Michael Fisher
1University of Liverpool
2Liverpool University Hospitals NHS Foundation Trust
Karen Martin
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Izabela Eberhart
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Christie Woods
2Liverpool University Hospitals NHS Foundation Trust
Sean Ewings
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Colin Hale
2Liverpool University Hospitals NHS Foundation Trust
Rajith KR Rajoli
1University of Liverpool
Laura Else
1University of Liverpool
Sujan Dilly-Penchala
1University of Liverpool
Alieu Amara
1University of Liverpool
David G Lalloo
4Liverpool School of Tropical Medicine
Michael Jacobs
4Liverpool School of Tropical Medicine
Henry Pertinez
1University of Liverpool
Parys Hatchard
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Robert Waugh
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Megan Lawrence
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Lucy Johnson
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Keira Fines
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Helen Reynolds
1University of Liverpool
Timothy Rowland
2Liverpool University Hospitals NHS Foundation Trust
Rebecca Crook
2Liverpool University Hospitals NHS Foundation Trust
Kelly Byrne
4Liverpool School of Tropical Medicine
Pavel Mozgunov
5MRC Biostatistics Unit, University of Cambridge
Thomas Jaki
5MRC Biostatistics Unit, University of Cambridge
Saye Khoo
1University of Liverpool
Andrew Owen
1University of Liverpool
Gareth Griffiths
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
Thomas E Fletcher
2Liverpool University Hospitals NHS Foundation Trust
4Liverpool School of Tropical Medicine
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions containing information that could compromise the privacy of research participants
Posted September 11, 2021.
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher
medRxiv 2021.09.10.21263376; doi: https://doi.org/10.1101/2021.09.10.21263376
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher
medRxiv 2021.09.10.21263376; doi: https://doi.org/10.1101/2021.09.10.21263376
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (679)
- Anesthesia (182)
- Cardiovascular Medicine (2687)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12318)
- Forensic Medicine (10)
- Gastroenterology (771)
- Genetic and Genomic Medicine (4161)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2699)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3935)
- Nursing (213)
- Nutrition (586)
- Oncology (2073)
- Ophthalmology (596)
- Orthopedics (243)
- Otolaryngology (308)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1131)
- Primary Care Research (462)
- Public and Global Health (6583)
- Radiology and Imaging (1424)
- Respiratory Medicine (877)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (55)
- Transplantation (191)
- Urology (170)